224 related articles for article (PubMed ID: 34282158)
1. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities.
Kriegova E; Fillerova R; Minarik J; Savara J; Manakova J; Petrackova A; Dihel M; Balcarkova J; Krhovska P; Pika T; Gajdos P; Behalek M; Vasinek M; Papajik T
Sci Rep; 2021 Jul; 11(1):14671. PubMed ID: 34282158
[TBL] [Abstract][Full Text] [Related]
2. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
3. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases.
Rasche L; Bernard C; Topp MS; Kapp M; Duell J; Wesemeier C; Haralambieva E; Maeder U; Einsele H; Knop S
Ann Hematol; 2012 Jul; 91(7):1031-7. PubMed ID: 22286070
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetics of extramedullary manifestations in multiple myeloma.
Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
[TBL] [Abstract][Full Text] [Related]
6. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
7. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma.
Smadbeck J; Peterson JF; Pearce KE; Pitel BA; Figueroa AL; Timm M; Jevremovic D; Shi M; Stewart AK; Braggio E; Riggs DL; Bergsagel PL; Vasmatzis G; Kearney HM; Hoppman NL; Ketterling RP; Kumar S; Rajkumar SV; Greipp PT; Baughn LB
Blood Cancer J; 2019 Dec; 9(12):103. PubMed ID: 31844041
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
[TBL] [Abstract][Full Text] [Related]
9. Molecular cytogenetic aberrations in Tunisian patients with multiple myeloma identified by cIg-FISH in fixed bone marrow cells.
Gmidène A; Avet-Loiseau H; Sennana H; Ben Abdallah I; Khlif A; Meddeb B; Elloumi M; Saad A
Cytogenet Genome Res; 2012; 136(1):44-9. PubMed ID: 22188899
[TBL] [Abstract][Full Text] [Related]
10. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
11. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
[TBL] [Abstract][Full Text] [Related]
12. Fluorescent in situ hybridization studies in multiple myeloma.
Yuregir OO; Sahin FI; Yilmaz Z; Kizilkilic E; Karakus S; Ozdogu H
Hematology; 2009 Apr; 14(2):90-4. PubMed ID: 19298720
[TBL] [Abstract][Full Text] [Related]
13. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
[TBL] [Abstract][Full Text] [Related]
14. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
[TBL] [Abstract][Full Text] [Related]
15. [Cytogenetic study of multiple myeloma].
Zhang Y; Jiang B; Huang XJ; Shi Y; He Q; Dang H; Qiu JY; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):76-8. PubMed ID: 17490526
[TBL] [Abstract][Full Text] [Related]
16. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.
Jelinek T; Zihala D; Sevcikova T; Anilkumar Sithara A; Kapustova V; Sahinbegovic H; Venglar O; Muronova L; Broskevicova L; Nenarokov S; Bilek D; Popkova T; Plonkova H; Vrana J; Zidlik V; Hurnik P; Havel M; Hrdinka M; Chyra Z; Stracquadanio G; Simicek M; Hajek R
Leukemia; 2024 Jun; 38(6):1323-1333. PubMed ID: 38493239
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.
Farre L; Sanz G; Ruiz-Xivillé N; Castro de Moura M; Martin-Tejera JF; Gonçalves-Ribeiro S; Martinez-Iniesta M; Calaf M; Luis Mosquera J; Martín-Subero JI; Granada I; Esteller M; Domingo-Domenech E; Climent F; Villanueva A; Sureda A
Dis Model Mech; 2021 Jul; 14(7):. PubMed ID: 33988237
[TBL] [Abstract][Full Text] [Related]
19. Prediction of cytogenetic abnormalities with gene expression profiles.
Zhou Y; Zhang Q; Stephens O; Heuck CJ; Tian E; Sawyer JR; Cartron-Mizeracki MA; Qu P; Keller J; Epstein J; Barlogie B; Shaughnessy JD
Blood; 2012 May; 119(21):e148-50. PubMed ID: 22496154
[TBL] [Abstract][Full Text] [Related]
20. Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH.
Smetana J; Dementyeva E; Kryukov F; Nemec P; Greslikova H; Kupska R; Mikulasova A; Ihnatova I; Hajek R; Kuglik P
Neoplasma; 2014; 61(1):48-55. PubMed ID: 24195508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
